Jinyu Bio-technology Co., Ltd. manufacturing and sales of veterinary biological drugs in China. The company offers various pig vaccines, including combined porcine circovirus type 2 and mycoplasma pneumoniae, classical swine fever, combined transmissible gastroenteritis and porcine epidemic diarrhea, swine influenza bivalent, porcine reproductive and respiratory syndrome, pseudorabies thermo-stable, porcine reproductive and respiratory syndrome virus, porcine circovirus type 2 baculovirus vector, combined transmissible gastroenteritis and porcine epidemic diarrhea, swine foot and mouth disease bivalent, porcine parvovirus, pseudorabies, haemophilus parasuis trivalent, and porcine circovirus type 2 vaccines. It also provides ruminant vaccines, such as foot and mouth disease trivalent, bovine pasteurella multocida, combined bovine viral diarrhea disease and infectious bovine rhinotracheitis, brucella gene deletion, goat pox, brucellosi, brucellosis, foot and mouth disease bivalent and type O, clostridium chauvoei, lumpy skin disease, combined ovine infectious necrotic hepatitis and braxy, and caprine infectious pleuropneumonia, as well as combined ovine braxy, struck, lamb dysentery, enterotoxaemia, and black disease and clostridium botulinum toxonosis vaccines. In addition, the company offers avian vaccines; rabies vaccines; and PCR and Elisa diagnostic kits. Further, it is involved in manufacturing and sales of veterinary chemical preparations, chemical reagents and auxiliary agents, biological drug preparations, and advanced medical equipment and instruments; biotechnology development, transfer, and consulting services; import and export of goods and technology; and provision of property management services. The company was founded in 1992 and is headquartered in Hohhot, China.
Metrics to compare | 600201 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship600201PeersSector | |
---|---|---|---|---|
P/E Ratio | 229.8x | 33.0x | −0.6x | |
PEG Ratio | −2.80 | 0.63 | 0.00 | |
Price/Book | 2.0x | 2.2x | 2.6x | |
Price / LTM Sales | 8.5x | 7.0x | 3.4x | |
Upside (Analyst Target) | −11.8% | 17.9% | 35.5% | |
Fair Value Upside | Unlock | 8.7% | 3.7% | Unlock |